FDA 483 - Grand River Aseptic Manufacturing, Inc. - September 19, 2024

An FDA inspection was conducted at Grand River Aseptic Manufacturing Inc in Grand Rapids, MI, from September 16 to September 19, 2024. The inspection resulted in observations documented on Form FDA 483, indicating areas requiring the company's attention concerning its manufacturing processes. Key issues identified include a deficiency in a fill validation study for syringe filling line 3, which failed to simulate all critical manufacturing steps for a specific product. Additionally, inspectors observed that not all unplanned operational and intervention activities, such as equipment repairs and breaches of the isolator environment during a mock fill run, were documented in a timely manner within the manufacturing batch records. These observations highlight concerns regarding process control and comprehensive documentation practices, which are fundamental to good manufacturing principles. Grand River Aseptic Manufacturing Inc is now expected to review these observations and provide a formal response to the FDA, detailing corrective and preventive actions to address the identified issues and ensure compliance with regulatory standards.